Search Results
Results found for "Zhan-Guo Gao"
- Structures of β 1-adrenergic receptor in complex with Gs and ligands of different efficacies
intermediate state complex comprising β1-AR and nucleotide-free Gs is more stable when binding a full agonist than
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
Vraniak’s career spans more than 20 years of financial and commercial experience in the life sciences
- Targeted Therapies to Reduce Side Effects in Modern Drug Development
In fact, it is often costly, frustrating, and tortuous—and more often than not it ends in failure.
- Discovery of 3(2-aminoethyl)-thiazolidine-2,4-diones as a novel chemotype of sigma-1 receptor ligand
Six compounds showed more than 50% displacement of the radioligand at 10 µM concentration with compound
- From Failed Experiments to Predictive GPCR Models
Rather than focusing solely on explaining receptor behavior post hoc, his group began developing workflows Carlsson notes that it’s easier to find pharmacologists to run assays than it is to persuade chemists
- VAMP2: a crucial player in the delivery of MOR to the synapse
Zhang, A.J.M. Molina, T.C. Südhof, and R.C. Malenka. 2013. Zhang, and L. Ma. 2008.
- GPCR Therapeutics welcomes Dr. Ed Brennan as their new Vice President, Head of Clinical Development
He has led teams that have filed more than 10 Investigational New Drug Applications (IND), as well as
- Bell-Evans model and steered molecular dynamics in uncovering the dissociation kinetics of ligands..
However, our predictions were many folds shorter than those determined experimentally.
- C5aR2 receptor: The genomic twin of the flamboyant C5aR1
C5aR2 is a nonclassical GPCR that tailors immune cell activity potentially through β-arrestins rather than
- Delineation of GPR15 receptor-mediated Gα protein signaling profile in recombinant mammalian cell
The results show that the GPR15 receptor preferentially couples to Gi/o rather than other pathways in
- Comparative studies of AlphaFold, RoseTTAFold and Modeller: a case study involving the use of...
program's top-scored structure, Modeller had the smallest average modeling RMSD of 2.17 Å, which is better than
- Design and validation of recombinant protein standards for quantitative Western blot analysis of...
density obtained by quantitative Western blot were of the same order of magnitude but slightly higher than
- How a Failed Experiment Created a Powerful GPCR Imaging Tool
therapeutic benefit Where not to target to avoid adverse effects Why GPCR Imaging Tools Matter More Than
- AlphaFold’s Breakthrough in GPCR Research: Revolutionizing Discovery, Yet Awaiting Experimental Proof
AlphaFold2 outperformed homology models, achieving a 60% hit rate for compounds targeting TAAR1, more than
- GASP1 enhances malignant phenotypes of breast cancer cells and decreases their response to...
was highly expressed in breast cancers, and patients harboring altered GASP1 showed a worse prognosis than
- GPCR Happy Hour – Boston, Sept 2025
GPCR Happy Hour is more than a social event.
- Target Residence Time: The Hidden Driver of In Vivo Efficacy
Time” Now Only in Terry’s Corner Why Terry’s Corner In a world where drug discovery is evolving faster than
- How Fast Does a Drug Work?
Why Faster, Smarter Decisions Require More Than Kd In drug discovery today, the clock is always ticking
- Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic ...
It is predicted that more than 50 GPCRs are expressed in the liver.
- Allosteric Binding Demystified: Smarter GPCR Drug Discovery
With Premium, you move faster, smarter, and more confidently than peers relying on scattered signals.
- Platelets in the NETworks interweaving inflammation and thrombosis
In light of the current COVID-19 pandemic, the topic of immunothrombosis has become more relevant than
- Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
Beyond the Curve: Questions This Lesson Helps You Answer This lesson pushes you to go deeper than surface-level
- Why Intracellular Drugs May Hold the Key to GPCR Therapeutics
Intracellular Drugs” Now Only in Terry’s Corner Why Terry’s Corner In a world where GPCR science moves faster than
- GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery
Cryptic Sites, Longer Onset: Why Some Drugs Work Differently in Cells Than in Assays One of the most
- Recurrent high-impact mutations at cognate structural positions in class A G protein-coupled ...
Because there are many more GPCRs than effectors, mutations in different receptors could perturb signaling
- Do You Believe AI Could Accelerate Drug Discovery?
Of 161 molecules tested, 42 substituted more than 50% of [³H]-LSD at 10 μM, achieving a 26% hit rate.
- Dynamic GPCR activation revealed through time-resolved Cryo-EM
of GPCR activation has always been a challenge because G protein activation in cells occurs in less than
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
These receptors have much larger binding pockets than the majority of GPCRs that have been successfully ’ interaction ensures that all molecules in the library are specific for the target receptor rather than either G protein signaling or arrestin signaling, and superagonists with signaling activity higher than conjugate exhibited poor selectivity for CCR5-expressing cells and was less effective at killing cells than Orion’s CCR2 antagonist analog (OB-004), discovered in only 6 months, is considerably more potent than
- From Farm Fields to GPCR Discovery, GLP-1 and GIP
Key next questions: Why do some patients respond better than others?
- How Schild Analysis Protects Your Conclusions in GPCR Research
Visualizing GLP-1 & GIP Receptors in Islets and Brain Understanding incretin biology depends on more than














